CDK inhibitors having 3-hydroxychromen-4-one structure
The present invention relates to a novel 3-hydroxychromen-4-one derivative represented by the following formula (1): A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ("CDK&...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Hong, Chang-Yong Lee, Jin-Ho Park, Tae-Sik Kim, Jong-Hyun Choi, Sei-Hyun Yoon, Sook-Kyung Chung, Hyun-Ho Son, Ho-Sun Kim, Eunice Eun-Kyeong Ro, Seong-Gu Jeong, Shin-Wu Kim, Dong-Myung |
| description | The present invention relates to a novel 3-hydroxychromen-4-one derivative represented by the following formula (1):
A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ("CDK") is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_06683095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>06683095</sourcerecordid><originalsourceid>FETCH-uspatents_grants_066830953</originalsourceid><addsrcrecordid>eNrjZDBzdvFWyMzLyEzKLMkvKlbISCzLzEtXMNbNqEwpyq-oTM4oys9NzdM10c3PS1UoLikqTS4pLUrlYWBNS8wpTuWF0twMCm6uIc4euqXFBYklqXklxfHpRYkgysDMzMLYwNLUmAglAEerLkM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CDK inhibitors having 3-hydroxychromen-4-one structure</title><source>USPTO Issued Patents</source><creator>Hong, Chang-Yong ; Lee, Jin-Ho ; Park, Tae-Sik ; Kim, Jong-Hyun ; Choi, Sei-Hyun ; Yoon, Sook-Kyung ; Chung, Hyun-Ho ; Son, Ho-Sun ; Kim, Eunice Eun-Kyeong ; Ro, Seong-Gu ; Jeong, Shin-Wu ; Kim, Dong-Myung</creator><creatorcontrib>Hong, Chang-Yong ; Lee, Jin-Ho ; Park, Tae-Sik ; Kim, Jong-Hyun ; Choi, Sei-Hyun ; Yoon, Sook-Kyung ; Chung, Hyun-Ho ; Son, Ho-Sun ; Kim, Eunice Eun-Kyeong ; Ro, Seong-Gu ; Jeong, Shin-Wu ; Kim, Dong-Myung ; LG Life Sciences Ltd</creatorcontrib><description>The present invention relates to a novel 3-hydroxychromen-4-one derivative represented by the following formula (1):
A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ("CDK") is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.</description><language>eng</language><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6683095$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64016</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6683095$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Hong, Chang-Yong</creatorcontrib><creatorcontrib>Lee, Jin-Ho</creatorcontrib><creatorcontrib>Park, Tae-Sik</creatorcontrib><creatorcontrib>Kim, Jong-Hyun</creatorcontrib><creatorcontrib>Choi, Sei-Hyun</creatorcontrib><creatorcontrib>Yoon, Sook-Kyung</creatorcontrib><creatorcontrib>Chung, Hyun-Ho</creatorcontrib><creatorcontrib>Son, Ho-Sun</creatorcontrib><creatorcontrib>Kim, Eunice Eun-Kyeong</creatorcontrib><creatorcontrib>Ro, Seong-Gu</creatorcontrib><creatorcontrib>Jeong, Shin-Wu</creatorcontrib><creatorcontrib>Kim, Dong-Myung</creatorcontrib><creatorcontrib>LG Life Sciences Ltd</creatorcontrib><title>CDK inhibitors having 3-hydroxychromen-4-one structure</title><description>The present invention relates to a novel 3-hydroxychromen-4-one derivative represented by the following formula (1):
A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ("CDK") is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZDBzdvFWyMzLyEzKLMkvKlbISCzLzEtXMNbNqEwpyq-oTM4oys9NzdM10c3PS1UoLikqTS4pLUrlYWBNS8wpTuWF0twMCm6uIc4euqXFBYklqXklxfHpRYkgysDMzMLYwNLUmAglAEerLkM</recordid><startdate>20040127</startdate><enddate>20040127</enddate><creator>Hong, Chang-Yong</creator><creator>Lee, Jin-Ho</creator><creator>Park, Tae-Sik</creator><creator>Kim, Jong-Hyun</creator><creator>Choi, Sei-Hyun</creator><creator>Yoon, Sook-Kyung</creator><creator>Chung, Hyun-Ho</creator><creator>Son, Ho-Sun</creator><creator>Kim, Eunice Eun-Kyeong</creator><creator>Ro, Seong-Gu</creator><creator>Jeong, Shin-Wu</creator><creator>Kim, Dong-Myung</creator><scope>EFH</scope></search><sort><creationdate>20040127</creationdate><title>CDK inhibitors having 3-hydroxychromen-4-one structure</title><author>Hong, Chang-Yong ; Lee, Jin-Ho ; Park, Tae-Sik ; Kim, Jong-Hyun ; Choi, Sei-Hyun ; Yoon, Sook-Kyung ; Chung, Hyun-Ho ; Son, Ho-Sun ; Kim, Eunice Eun-Kyeong ; Ro, Seong-Gu ; Jeong, Shin-Wu ; Kim, Dong-Myung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_066830953</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2004</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Hong, Chang-Yong</creatorcontrib><creatorcontrib>Lee, Jin-Ho</creatorcontrib><creatorcontrib>Park, Tae-Sik</creatorcontrib><creatorcontrib>Kim, Jong-Hyun</creatorcontrib><creatorcontrib>Choi, Sei-Hyun</creatorcontrib><creatorcontrib>Yoon, Sook-Kyung</creatorcontrib><creatorcontrib>Chung, Hyun-Ho</creatorcontrib><creatorcontrib>Son, Ho-Sun</creatorcontrib><creatorcontrib>Kim, Eunice Eun-Kyeong</creatorcontrib><creatorcontrib>Ro, Seong-Gu</creatorcontrib><creatorcontrib>Jeong, Shin-Wu</creatorcontrib><creatorcontrib>Kim, Dong-Myung</creatorcontrib><creatorcontrib>LG Life Sciences Ltd</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Hong, Chang-Yong</au><au>Lee, Jin-Ho</au><au>Park, Tae-Sik</au><au>Kim, Jong-Hyun</au><au>Choi, Sei-Hyun</au><au>Yoon, Sook-Kyung</au><au>Chung, Hyun-Ho</au><au>Son, Ho-Sun</au><au>Kim, Eunice Eun-Kyeong</au><au>Ro, Seong-Gu</au><au>Jeong, Shin-Wu</au><au>Kim, Dong-Myung</au><aucorp>LG Life Sciences Ltd</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CDK inhibitors having 3-hydroxychromen-4-one structure</title><date>2004-01-27</date><risdate>2004</risdate><abstract>The present invention relates to a novel 3-hydroxychromen-4-one derivative represented by the following formula (1):
A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ("CDK") is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_06683095 |
| source | USPTO Issued Patents |
| title | CDK inhibitors having 3-hydroxychromen-4-one structure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T02%3A45%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Hong,%20Chang-Yong&rft.aucorp=LG%20Life%20Sciences%20Ltd&rft.date=2004-01-27&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E06683095%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |